Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.

To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.

This study aims to prospectively evaluate the effectiveness of the Composite Immune Risk Score in real-world clinical setting.

Inclusion Criteria:

• 1) Patients must be ≥ 16 years of age;
• 2) Patients receiving haploidentical allo-HSCT;
• 3) Patients have to sign an informed consent form before the start of the research procedure.

Exclusion Criteria:

• 1) Tandem transplantation or multiple transplantations;
• 2) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
• 3) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.